Just raising the alarm won’t drive action. Use these three steps to turn insights into solutions that leadership can’t ignore ...

Analysts at BMO Capital Markets expect Summit and Akeso’s HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

The so-called 'Most Favored Nations' rule would set drug pricing for Medicare in line with the prices paid by other nations, ...

An HHS spokesperson said the agency has not yet made a final decision regarding changes to the COVID-19 vaccination ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity ...

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

In December 2024, the FDA affirmed that the tirzepatide shortage had ended, formally barring compounders from producing their ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to ...